Osteoprotegerin and denosumab in pathophysiology and pharmacotherapy of postmenopausal osteoporosis

Abstract

Denosumab is the first fully human monoclonal antibody that inhibits the formation, function, and survival of osteoclasts by blocking the interaction of receptor activator of nuclear factor-kappaB (RANK) ligand with its osteoclastic receptor RANK. Decrease in osteoclastic bone resorption is fully reversible.

Keywords

• osteoprotegerin
• denosumab
• fracture
• treatment
• osteoporosis